Search
TW-37
go.drugbank.com/drugs/DB17059ExperimentalTW-37 is a small-molecule inhibitor of Bcl-2 investigated for its anti-cancer properties.[A253157]
Boldenone
go.drugbank.com/drugs/DB01541ExperimentalIllicitVet approvedBoldenone is an anabolic steroid developed for veterinary use, mostly for treatment of horses. It is not indicated for use in humans in the US and is only available through veterinary clinics.
PRO-542
go.drugbank.com/drugs/DB05793InvestigationalPRO 542 belongs to a new class of drugs, viral-entry inhibitor, which is intended to prevent HIV from entering and infecting cells.
AVI-5126
go.drugbank.com/drugs/DB05726InvestigationalAVI-526 is an improved formulation of [AVI-4557], developed for use on Vein Grafts before use in Heart by-Pass Graft Surgery. … AVI-526 works by silencing a gene known as c-myc, a key regulatory gene involved in cardiovascular restenosis.
Synonyms: Resten-CP(TM)Aglatimagene besadenovec
go.drugbank.com/drugs/DB15074InvestigationalAglatimagene besadenovec is under investigation in clinical trial NCT00638612 (AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)).
Synonyms: ADV-TKUdifitimod
go.drugbank.com/drugs/DB19053InvestigationalUdifitimod is under investigation in clinical trial NCT05014438 (A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis).
5-androstenedione
go.drugbank.com/drugs/DB01456ExperimentalIllicitApart from the positioning of a carbon-carbon double bond, its structure is similar to [4-androstenedione], which is a prohormone which is naturally produced in the body by the adrenal glands and gonads … , and acts as precursor to testosterone, as well as estrone and estradiol.
Covax-19™
go.drugbank.com/drugs/DB15846InvestigationalPhase 2 and 3 trials are planned for September 2020, and the vaccine is expected to launch early in 2021. … Covax-19™ was tested in animal studies, and shown to achieve potent antibody and T-cell responses against the COVID-19 spike protein.
AVI-4065
go.drugbank.com/drugs/DB05620InvestigationalIt was developed by Sarepta Therapeutics, Inc. After phase II trials it was cancelled due to lack of potency. [L2917]
Cetuximab sarotalocan
go.drugbank.com/drugs/DB19240InvestigationalCetuximab sarotalocan is under investigation in clinical trial NCT03769506 (ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy … ) for the treatment of Recurrent Head/Neck Cancer.